Early high-sensitivity troponin elevation

- ² in predicting short-term mortality in
- ³ sepsis: A protocol for a systematic
- 4 review with meta-analysis

6	Santiago Ferrière-Steinert ¹ , Joaquín Valenzuela Jiménez ¹ , Sebastián Heskia Araya ¹ ,
7	<i>Thomas Kouyoumdjian Carvajal¹, José Ramos-Rojas^{2,3,}</i> , Abraham I. J. Gajardo ^{4,5*}
8	
9	¹ School of medicine, Faculty of medicine, Universidad de Chile, Santiago, Chile
10	² Epistemonikos Foundation, Santiago, Chile
11	³ Carrera de odontología, Facultad de medicina Clínica Alemana Universidad del Desarrollo,
12	Santiago de Chile
13	⁴ Intensive Care Unit, Department of Internal Medicine, Hospital Clínico Universidad de
14	Chile, Santiago Chile
15	⁵ Program of Pathophysiology, Institute of Biomedical Science, Faculty of Medicine,
16	Universidad de Chile, Santiago, Chile
17	* Corresponding Author

18 E-mail: aij.gajardo@gmail.com (AIJG)

⁵

19 Abstract

20	Background: Sepsis is a common admission diagnosis in the intensive care unit (ICU). The
21	Sepsis-3 consensus associates sepsis diagnosis with acute organ dysfunction. In these
22	patients troponin elevation is a well-established phenomenon, but its clinical significance is
23	not settled, as no systematic review has addressed the prognostic significance of the
24	increasingly prevalent high-sensitivity troponin assays in acute organ dysfunction setting.
25	This study aims to clarify the association between early serum troponin levels in high-
26	sensitivity assays with short-term mortality risk in septic patients with acute organ
27	dysfunction.
28	Methods: We will systematically search PubMed, Scopus and Embase for original articles;
29	additionally, a manual search will be carried out through relevant literature. Generally,
30	studies will be deemed eligible for inclusion if they evaluate the association between high-
31	sensitivity troponin in the first 24 hours of admission and ICU, 30-days, or In-hospital
32	mortality; in patients with septic shock or sepsis related to acute organ dysfunction. Two
33	reviewers will independently select studies and extract the data. A meta-analysis for
34	mortality outcome will be performed for comparative data regarding two effect measures:
35	Odd ratios and Standardized Mean differences.
36	Discussion: This study will provide further evidence about the role of high-sensitivity
37	troponin assays in predicting mortality in septic patients; potentially helping to guide further
38	research and yielding valuable information for patient assessment.
39	Conclusion about the certainty of evidence will be presented in a 'Summary of findings'
40	table.

41 **PROSPERO registration:** (CRD42024468883)

Key words: systematic review; meta-analysis; prognostic factor; prognosis; troponin; highsensitivity troponin; sepsis; septic shock; septic cardiomyopathy

44 **1. Background**

45 Sepsis is the most common mortality cause in Intensive Care Unit (ICU) patients in the

46 United States. A fourth of patients diagnosed with sepsis will die within their hospitalization,

47 rising to a half within the septic shock group (1). Furthermore, sepsis-related deaths have

48 been on the rise in the US and worldwide (1–3), and are expected to continue to do so.

49 Sepsis definitions have varied throughout the years. Sepsis-3 consensus, agreed in 2016,

50 defines sepsis as a life-threatening organ dysfunction (assessed by SOFA score) in behalf of

an infection; disposing of the former category of severe sepsis while preserving septic shock

52 (4). Thus, compared with previous sepsis definitions, patients diagnosed with sepsis-3

53 criteria are exposed to an increased mortality and adverse events risk (5).

54 Sepsis is associated with complications and dysfunction of several systems (6). At the 55 cardiac level, sepsis is well-documented to be associated with acute myocardial injury 56 independent of coronary perfusion abnormality (7). This phenomenon is primarily attributed 57 to inflammatory and cardio-depressant factors that act indirectly and directly on the 58 cardiomyocyte (7,8). Furthermore, when the myocardial injury ensues in diastolic and/or 59 systolic dysfunction, it is considered Septic Cardiomyopathy (7). Although there is no 60 consensus on the criteria for this entity, commonly accepted cardinal features are: The 61 absence of an underlying coronary etiology, the acute presentation, and the reversibility of 62 the dysfunction (7–9).

Cardiac troponins are widely used in the diagnosis of acute coronary syndrome and other
 cardiac pathologies presenting with myocardial injury (10), including sepsis. High-sensitivity
 cardiac troponin assays (hs-cTn) are usually defined by their capacity to detect troponin in at

least 50% of healthy individuals (10,11). In recent years hs-cTn have increasingly replaced
conventional assays since they have both a lower limit of detection, and a lower and
categorically defined normality cut-off. Thus, a hs-cTn level above the 99th percentile for the
healthy population allows for a precise differentiation between *normal* and *elevated* groups
(11).

71 Troponin elevation in septic patients is well-established but debated as a prognostic risk 72 factor for clinical outcomes (7,12). Three meta-analyses have been published on the issue 73 (13–15), all showed a significant association of troponin elevation with increased mortality, 74 but suffer from many problems of published data on troponin and mortality in sepsis: Lack of 75 strict or similar criteria for sepsis diagnosis, heterogeneity of sampling time, usage of 76 conventional rather than hs-cTn essays, and absence of controlling of confounders (7). 77 Moreover, the emergence and consolidation of Sepsis-3 definition, and the rise of hs-cTn 78 assays could impact on the stratification of patients, modifying the prognostic association of 79 the biomarkers with mortality risk (16). Consequently, it is currently unknown if elevation in 80 hs-cTn levels is associated with mortality risk in patients with sepsis by Sepsis-3 consensus. 81 This study aims to assess the association of early high-sensitivity serum troponin levels with 82 short-term mortality in patients admitted to ICU because of sepsis with acute organ 83 dysfunction.

84

1. Methods

86 2.1. Registration

87 The protocol was registered on the International Prospective Register of Systematic reviews
88 (CRD42024468883). This protocol aligns with Preferred Reporting Items for Systematic

- review and Meta-Analysis Protocols (PRISMA-P) statement (17), and follows Riley's guide
 for systematic review of prognostic factors (18). Deviations from protocol will be recognized
 in the final article.
- 92 2.2. Literature search
- 93 With the help of a knowledgeable librarian a search strategy was created: Pubmed, Scopus
- 94 and Embase will be searched for primary articles published in English and involving humans,
- 95 with no date restrictions. The prepared search strings combine free text and
- 96 MeSH/EMTREE terms for all words related to troponin and sepsis (see Table 1). No
- 97 additional filters besides the ones described in the strings will be utilized.

98 Table 1. Search strings utilized

Pubmed	(((("troponin i"[MeSH Terms]) OR ("troponin"[MeSH Terms])) OR ("troponin c"[MeSH
string	Terms])) OR ("troponin t"[MeSH Terms]) OR ("troponin*"[All Fields]) AND
	((humans[Filter]))) AND ((("sepsis"[MeSH Terms]) OR ("shock, septic"[MeSH Terms]))
	OR (Systemic Inflammatory Response Syndrome[MeSH Terms]) AND ((humans[Filter])))
SCOPUS	(TITLE-ABS-KEY (troponin) AND TITLE ((sepsis) OR (septic AND shock)) AND
string	KEY((sepsis)OR(septic AND shock)))
EMBASE	'sepsis'/exp/mj AND troponin* AND [humans]/lim
string	

- 100 Subsequently, we will manually scrutinize references of included studies and previous
- 101 reviews on the topic to retrieve missing pertinent papers.

Searches will be re-run just before the final analyses to check for new studies that meet theinclusion criteria.

104 2.3. Study selection

- 105 In accordance to CHARMS guidance (19), the research question was formulated with the
- 106 Population/Index prognostic factor/Comparator prognostic factors/Outcome/Timing/Setting
- 107 (PICOTS) system, a modified version of the traditional PICO, where the P and O remains the
- same as the original, but the *I* stands for *Index prognostic factors* and *C* for other prognostic
- 109 factors that can be considered as Comparators (18). (See table 2 for details on the defined
- 110 scope of the systematic review). For the determination of inclusion and exclusion criteria
- 111 table 3 was constructed.

	Definition
Population	Adults diagnosed with sepsis with acute organ dysfunction
Index	High-sensitivity troponin levels in serum
prognostic	
factor	
Comparator	Studies with or without comparators will be included.
Timing	1. Troponin sampling upon admission or within the first 24 hours.
	2. In-hospital or 30-days mortality
Outcome	All-cause mortality
Setting	Emergency department (ED) or Intensive Care Unit (UCI)

112 Table 2. PICOTS for the scope of the systematic review

113 Table 3. Inclusion and exclusion criteria for the systematic review

	Inclusion criteria	Exclusion criteria
Population	 Individuals >18 years old of any gender and any ethnicity in any country Individuals that were diagnosed with sepsis or septic shock according to sepsis-3 criteria, or with Severe sepsis or Septic shock according to Sepsis-1 or Sepsis-2 criteria. 	 Studies with mixed or uniquely underaged samples Studies with ≤ 10 events (i.e. deaths) per study Sepsis is not the primary diagnosis. Letters to the Editor, Case reports, reviews, meta-analysis, and non-primary studies in general Studies restricted to a specific pathology (e.g studies focusing exclusively on COVID or Cancer patients) The paper refers to a sample already used by another paper in the corpus of studies
Index	Studies explicitly	Studies not publishing extractable numeric
prognostic	declaring the utilization	data on troponin measurements, who fail to
factor	of any High-sensitivity	answer attempts to be contacted.
	cardiac troponin	 Studies explicitly declaring the utilization of
	(cTnT, cTnI, or cTnC)	non high-sensitivity essays
	essay	e If no statement is made on the LoD of well
	If no explicit statement	 If no statement is made on the LoD as well, studies with normal limit cutoff > 20 ng/L will

	is made on the sensitivity, essays will be regarded as high- sensitivity if their declared Limit of Detection (LoD) is ≤ 5 ng/L	 be excluded. Studies that fail to publish either the sensitivity of their essays, the Limit of Detection (LoD) or their normal cutoff value; and fail to answer contact attempts
Comporator	Not applicable	Not applicable
Comparator		
Outcome	All-cause mortality	 Studies that didn't report any form of
	reported through	association between the pertinent troponin
	hospital reports or	levels and the pertinent mortality.
	other validated source	
Timing	First troponin	Studies where the first reported troponin
	measurement within	levels measurement occurred beyond the
	the first 24 hours of	first 24 hours after admission.
	admission	
	Studies that include In-	
	hospital mortality or	
	follow-up mortality at	
	most 30 days from	
	admission.	
Setting	Patients in ICU or Emergency	Other settings, including non-clinical context (e.g.

	department (ED)	experimentation)
Language	English studies	No original English version could be obtained.
Publication	Published studies,	Other publication status, including retracted papers.
status	conferences or abstracts.	Published abstracts where no access to the cohort characteristics could be obtained after appropriate contact attempts.
Species	Human studies	Animal studiesIn vitro studies

114 Based on this criteria, after deleting duplicates the corpus of studies will be scanned in

115 Rayyan (20) by two independent reviewers, discrepancies will be solved by a third reviewer.

116 Studies will be discarded based on 1 criterion only.

117 Studies will be first analyzed based on their title and abstract. Papers that pass this primary

scrutiny, or whenever it seems insufficient, will be subject to full text assessment by the

119 same reviewers for final selection.

120 Basically, interventional and observational primary studies will be deemed eligible if they

reported some form of association between troponin levels and mortality in a general clinical

122 context. We will only include studies that report on patients diagnosed either with sepsis by

123 Sepsis-3 criteria (4), with Severe sepsis by Sepsis-1 or Sepsis-2 (21,22), or Septic shock by

any of them (4,21,22). Selection will be restricted to studies that specify the utilization of any

125 hs-cTn assay in the first 24 hours after hospital admission, or whose reported limit of

- 126 detection we consider high-sensitivity (i.e. < 9 ng/L)(10). In the case that the latter
- 127 information about the assays is omitted, we will exclude studies if they fail to meet a
- 128 normality cutoff of 20 ng/L or lower, since they will be regarded as having a cutoff over the

- 129 99th percentile of the healthy population and therefore considered as non hs-cTn assay,
- 130 based on European Society of Cardiology guidelines (10).
- 131 The study selection process will be reported using the PRISMA flowchart, providing a clear
- 132 visual representation of the inclusion and exclusion criteria application (17).

133 **2.4. Data extraction**

- 134 Based on CHARMS-PF checklist (18) we designed a standardized data extraction form,
- 135 containing the relevant characteristics of studies to be included (table 4). Data will be
- 136 extracted by two reviewers. Types of reported associations suitable to be extracted for this
- table are: 1) "dose-response": data reported as odds, risk, or hazard ratio per unit increase in
- exposure; 2) "category/quantile based": numbers (ideally 2x2 tables) or ratios comparing
- 139 groups as defined by quantiles or categories of exposure; 3) "means": data reported as
- 140 means or mean differences in exposure, comparing those presenting and not presenting the
- 141 event (23). If a study presents more than one of these associations, we will extract all of
- 142 them.

143 Table 4. Data extraction form

		Number	Setting	Eligibility	Age	Male (%)	Study	Exclud	
		of	and	and			type	ed	
		patients	country	recruiting				comor	
				methods				bidities	
				(multicenter					
Article				or					Sepsis/Septi
and				monocenter					c shock
Author	Year)					definition

145

measure(s Troponin type statistical multivariate	
Mortality) with used and analysis analysis (if	
Shock Mortality time follow- Standard normality any) Quality	Score
(%) (%) up Error(s) cutoff (QUIPS))

146

147	We will collect extracted effect measures together with their standard errors (SE). If SEs are
148	not explicitly available, we will derive them from metrics such SDs, exact p-values, or
149	confidence intervals (24). We will collect adjusted and unadjusted effect measures
150	separately. If many adjusted models are presented, we will extract the one which fits better
151	the core adjustment factors selected (see Risk of Bias section). If effect measures for
152	several time points are presented, we will prioritize ICU and 28-mortality (in that order) over
153	in-hospital mortality. If effect measures for several hs-cTn samples are presented, we will
154	prioritize the sample extracted closest to ED/ICU admission. Data only presented as figures
155	will be extracted with WebPlotDigitizer software (25).
156	Authors will be contacted to request critical missing or not reported data regarding
157	associations of interest. In case of no response, the article will be excluded from this study.
158	We will present a summarized version of this table in the final review.

2.5. Risk of bias assessment 159

160 Bearing in mind the prognostic nature of the review and taking into account previously 161 published meta-analysis (13-15), we can expect that mainly observational studies will be 162 included.

163 Two authors will independently assess the risk of bias (RoB) applying the QUIPS (quality in 164 prognostic factor studies) tool (26), and then discuss together their assessments in order to 165 decide the final score. In QUIPS RoB assessments are made within a set of 6 domains: (1) 166 Study Participation, (2) Study Attrition, (3) Prognostic Factor Measurement, (4) Outcome 167 Measurement, (5) Study Confounding and (6) Statistical Analysis and Reporting. We defined 168 Study participation. Prognostic Factor Measurement and Study Confounding as the key 169 domains for our assessment, and we specified criteria for each of these domains. For the 170 confounder domain RoB evaluation, we will look for 3 core adjustment factors in each study: 171 severity of sepsis, age, and comorbidities (any cardiac or renal). 172 Classification for each RoB item could be 'low', 'moderate', or 'high'. Moreover, this

assessment will include an overall judgment concerning the total RoB quality of each study,

174 which will be visualized in the review.

175 **2.5. Statistical analysis**

We will investigate the mortality outcome with two effect measures: Mortality risk and Meandifference in troponin distribution.

178 1) Regarding mortality risk analysis: Whenever feasible a 2x2 contingency table will be 179 gathered from available data, with one axis for survivor vs non-survivor groups, and other for 180 elevated vs normal troponin level group, according to the cut-off defined by every study for 181 each specific hs-cTn assay. If the sample is divided into more than 2 groups or categories 182 (e.g. quantiles) it will be dichotomized around the closest match to a normality cutoff of 15 183 ng/L (27). We will add 0.5 to each cell in any table that contains one or more zero values 184 (24). We will compute an Odds Ratio (OR) with its SE from this contingency table for each 185 study. For studies not presenting sufficient data for a contingency table we will extract 186 explicitly reported unadjusted ORs with their SEs. ORs from studies handling hs-cTn as a

continuous variable (i.e. dose-response) will be scaled to an OR per 50 ng/L of increment.
This magnitude was considered representative of the difference between the group usually
referred to as "normal" compared to the "elevated" troponin level group –based on the
reported troponin distributions of pertinent studies known to us and in accordance with our
clinical expert (28–30).

192 Results from studies reporting Hazard Ratio (HR) or Relative Risk (RR) will be presented

separately. Only if the event probability in the control group is <0.2, and the HR or RR are

194 below 2.5, the effect measures will be interpreted as numerically equivalent to an OR and

195 reported together with the other studies (31).

196 With these effect measures we will perform a structured quantitative analysis (meta-analysis)

197 for the pooled unadjusted mortality effect.

198 ORs of adjusted (i.e. multivariate) regressions will be included in a separate model for the

adjusted mortality effect regardless of the set of confounders controlled for. We will reportvariables incorporated in the regression for each study in a table.

201 2) For difference in troponin levels analysis: Studies presenting mean difference data in

troponin level by survivor status will be meta-analyzed in a single model using Hedges' g

203 Standardized Mean Differences (SMD).

All models will be generated using R-4.3.1 package *metafor* (32), utilizing the random-effects model and the inverse variance weighting method (24).

206 Heterogeneity will be assessed and reported by I2 statistic, where >50% and a p-value <

207 0.10 are of concern and will be further explored (24).

208 Studies not presenting minimum data (e.g. missing SE) will be included in the narrative

synthesis and compared to the results of the meta-analysis to the extent possible.

- 210 For the sake of replicability all formulas, raw data, and calculations shall be included either in
- 211 the article itself or an online supplement.

212 **2.6. Subgroup and sensitivity analysis**

- 213 Models will undergo a comprehensive heterogeneity assessment. Since reviews of
- 214 prognostic studies usually can result in high I2 regardless of similar point estimates (33), we
- 215 will favor visual inspection over statistical criteria.
- 216 If in any of the model's heterogeneity is deemed substantial, we will run the following
- 217 Subgroup analysis:
- 218 **1. Subgroups by shock status:** To assess whether effect measures and
- heterogeneity is significantly dependent on the degree of organic dysfunction, we will
 proceed with a subgroup analysis between studies restricting inclusion criteria to
 septic shock only, versus studies that encompass patients with sepsis, severe sepsis
 and septic shock.
- Subgroup by type of troponin: Despite the fact that troponin essays have longed
 being considered equivalent in the acute coronary syndrome setting (34), emergency
 evidence supports that hs-cTnT and hs-cTnI outcome prognostic value might differ in
 other scenarios (35,36). To assess if such a difference exists in this case, we will
 group studies by the declared essay type (i.e. hs-cTnI, hs-cTnC).
- 3. Subgroup by type of association: In order to assess whether heterogeneity may
 be due to the type of analysis employed to derive a dichotomous effect size, a
- 230 subgroup analysis will be performed segregating studies reporting dose-response
- 231 data (i.e. regressions handling hs-cTn as a continuous dependent variable) versus
- 232 category/quantile-based data (i.e. contingency tables and/or regressions handling hs-

cTn as a dichotomous dependent variable). This subgrouping is not applicable for theSMD model.

235 Furthermore, to assess whether missing adjustment for relevant confounders might be

impacting the heterogeneity and pooled effect size of the mortality adjusted model: We will

237 undertake a sensitivity analysis, meta-analyzing only effect measures of studies adjusting for

238 (at least) the 3 predefined core confounders.

239 To avoid p-value overreliance, the credibility of the differential effect of statistically significant

240 Subgroup analysis will be critically appraised with the ICEMAN questionnaire (37).

If we suspect a small study effect in any model, we will run a sensitivity analysis with a fixedeffect model.

243 **2.8. Publication bias**

244 For assessment of possible small-study effect, we will generate funnel plots for each model

245 plotting the logarithm of the obtained odds ratios against their standard error (38).

We will visually inspect the plots for signs of publication bias (namely, asymmetry)(18,39). If more than 10 (for the sake of statistical power) studies are included in the model, we will run an Egger's test (40).

3. Discussion and Conclusions

The prognostic significance of troponin for sepsis outcomes is not yet settled. Although previous works have consistently shown a significant association between troponin and mortality, there is a need for more research shedding light on the prognostic value of such biomarker for the most common current clinical setting in the ICU. This study will provide further evidence about the role of hs-cTn assays in predicting mortality in septic patients;

potentially helping to guide further research and yielding valuable information for patientassessment.

- 257 We will evaluate the certainty of evidence for each investigated outcome with the 'Grading of
- 258 Recommendations Assessment, Development and Evaluation' (GRADE) system guideline
- appropriate for synthesis of prognostic factors evidence (41,42). A "Summary of findings'
- table will communicate with standardized statements the certainty of this evidence

261 Supporting information

- 262 S1 Checklist. PRISMA-P (Preferred Reporting Items for Systematic review and Meta-
- 263 Analysis Protocols) 2015 checklist: Recommended items to address in a systematic
- 264 review protocol*. (DOC1)

265 Author Contributions

- 266 **Conceptualization:** Santiago Ferrière-Steinert, Abraham I. J. Gajardo Cortez, José Ramos-
- 267 Rojas
- 268 Formal analysis: Santiago Ferrière-Steinert, Joaquín Valenzuela Jiménez, Sebastián
- 269 Heskia Araya, Thomas Kouyoumdjian Carvajal
- 270 Project administration: Santiago Ferrière-Steinert, Abraham I. J. Gajardo Cortez
- 271 Resources: Abraham I. J. Gajardo Cortez
- 272 Supervision: Abraham I. J. Gajardo Cortez
- 273 Validation: Santiago Ferrière-Steinert, Abraham I. J. Gajardo Cortez
- 274 Writing original draft: Santiago Ferrière-Steinert, Joaquín Valenzuela Jiménez,
- 275 Sebastián Heskia Araya, Thomas Kouyoumdjian

276 Writing – review & editing: Abraham I. J. Gajardo Cortez, José Ramos-Rojas

277

278

279 **References**

- Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014 Jan
 1;5(1):4–11.
- Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United
 States from 1979 through 2000. N Engl J Med. 2003 Apr 17;348(16):1546–54.
- Kumar G, Kumar N, Taneja A, Kaleekal T, Tarima S, McGinley E, et al. Nationwide
 trends of severe sepsis in the 21st century (2000-2007). Chest. 2011 Nov;140(5):1223–
 31.
- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.
 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
- 289 JAMA. 2016 Feb 23;315(8):801–10.
- 5. Eriksson J, Eriksson M, Brattström O, Hellgren E, Friman O, Gidlöf A, et al. Comparison
 of the sepsis-2 and sepsis-3 definitions in severely injured trauma patients. Journal of
 Critical Care. 2019 Dec 1;54:125–9.
- Font MD, Thyagarajan B, Khanna AK. Sepsis and Septic Shock Basics of diagnosis,
 pathophysiology and clinical decision making. Med Clin North Am. 2020 Jul;104(4):573–
 85.

296 7. Ehrman RR, Sullivan AN, Favot MJ, Sherwin RL, Reynolds CA, Abidov A, et al.

297 Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic

implications of septic cardiomyopathy: a review of the literature. Crit Care. 2018
 Dec;22(1):112.

L'Heureux M, Sternberg M, Brath L, Turlington J, Kashiouris MG. Sepsis-Induced
 Cardiomyopathy: a Comprehensive Review. Curr Cardiol Rep. 2020;22(5):35.

Sato R, Nasu M. A review of sepsis-induced cardiomyopathy. Journal of Intensive Care.
 2015 Nov 11;3(1):48.

304 10. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC

305 Guidelines for the management of acute coronary syndromes in patients presenting

306 without persistent ST-segment elevation. European Heart Journal. 2021 Apr

307 7;42(14):1289–367.

308 11. Twerenbold R, Jaffe A, Reichlin T, Reiter M, Mueller C. High-sensitive troponin T

309 measurements: what do we gain and what are the challenges? European Heart Journal.

310 2012 Mar 1;33(5):579–86.

- 311 12. The Septic Heart: Current Understanding of Molecular Mechanisms and Clinical
 312 Implications. Chest. 2019 Feb 1;155(2):427–37.
- 313 13. Sheyin O, Davies O, Duan W, Perez X. The prognostic significance of troponin elevation
 314 in patients with sepsis: a meta-analysis. Heart Lung. 2015;44(1):75–81.
- 315 14. Bessière F, Khenifer S, Dubourg J, Durieu I, Lega JC. Prognostic value of troponins in
- 316 sepsis: a meta-analysis. Intensive Care Med. 2013 Jul;39(7):1181–9.

- 317 15. Zheng P, Wang X, Guo T, Gao W, Huang Q, Yang J, et al. Cardiac troponin as a
- 318 prognosticator of mortality in patients with sepsis: A systematic review and meta-
- analysis. Immun Inflamm Dis. 2023 Sep;11(9):e1014.
- 320 16. Røsjø H, Varpula M, Hagve TA, Karlsson S, Ruokonen E, Pettilä V, et al. Circulating
- high sensitivity troponin T in severe sepsis and septic shock: distribution, associated
- factors, and relation to outcome. Intensive Care Med. 2011 Jan;37(1):77–85.
- 17. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ.
- 325 2021 Mar 29;372:n71.
- 326 18. Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, et al. A guide to
- 327 systematic review and meta-analysis of prognostic factor studies. BMJ. 2019 Jan
 328 30;364:k4597.
- 19. Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al.
- 330 Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling
- 331 Studies: The CHARMS Checklist. PLoS Med. 2014 Oct 14;11(10):e1001744.
- 332 20. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app
 333 for systematic reviews. Systematic Reviews. 2016 Dec 5;5(1):210.
- 334 21. American College of Chest Physicians/Society of Critical Care Medicine Consensus
- 335 Conference: Definitions for sepsis and organ failure and guidelines for the use of
- innovative therapies in sepsis. Critical Care Medicine. 1992 Jun;20(6):864.
- 337 22. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001
- 338 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care
- 339 Med. 2003 Apr;31(4):1250–6.

- 340 23. Bekkering GE, Harris RJ, Thomas S, Mayer AMB, Beynon R, Ness AR, et al. How Much
- 341 of the Data Published in Observational Studies of the Association between Diet and
- 342 Prostate or Bladder Cancer Is Usable for Meta-Analysis? American Journal of
- 343 Epidemiology. 2008 May 1;167(9):1017–26.
- 344 24. Higgins JPT, Cochrane Collaboration, editors. Cochrane handbook for systematic
- 345 reviews of interventions. Second edition. Hoboken, NJ: Wiley-Blackwell; 2020.
- 346 (Cochrane book series).
- 347 25. Rohatgi A. Webplotdigitizer: Version 4.6 [Internet]. 2022. Available from:
- 348 https://automeris.io/WebPlotDigitizer

349 26. Grooten WJA, Tseli E, Äng BO, Boersma K, Stålnacke BM, Gerdle B, et al. Elaborating
350 on the assessment of the risk of bias in prognostic studies in pain rehabilitation using
351 QUIPS—aspects of interrater agreement. Diagnostic and Prognostic Research. 2019
352 Mar 7;3(1):5.

27. Hamling J, Lee P, Weitkunat R, Ambühl M. Facilitating meta-analyses by deriving
relative effect and precision estimates for alternative comparisons from a set of
estimates presented by exposure level or disease category. Statistics in Medicine. 2008
Mar 30;27(7):954–70.

28. Xu KZ, Xu P, Li JJ, Zuo AF, Wang SB, Han F. Predictors and nomogram of in-hospital
mortality in sepsis-induced myocardial injury: a retrospective cohort study. BMC
Anesthesiol. 2023 Jul 7;23(1):230.

360 29. Vallabhajosyula S, Sakhuja A, Geske JB, Kumar M, Poterucha JT, Kashyap R, et al.

- 361 Role of Admission Troponin-T and Serial Troponin-T Testing in Predicting Outcomes in
- 362 Severe Sepsis and Septic Shock. J Am Heart Assoc. 2017 Sep 9;6(9):e005930.

- 363 30. Vallabhajosyula S, Sakhuja A, Geske JB, Kumar M, Kashyap R, Kashani K, et al.
- 364 Clinical profile and outcomes of acute cardiorenal syndrome type-5 in sepsis: An eight-
- 365 year cohort study. PLoS One. 2018 Jan 9;13(1):e0190965.
- 366 31. Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. J Clin
 367 Epidemiol. 2002 Sep;55(9):893–9.
- 368 32. Viechtbauer W. Conducting meta-analyses in R with the metafor package. Journal of
 369 Statistical Software. 2010;36(3):1–48.
- 370 33. Guyatt G, Zhao Y, Mayer M, Briel M, Mustafa R, Izcovich A, et al. GRADE guidance 36:
- 371 updates to GRADE's approach to addressing inconsistency. Journal of Clinical
- 372 Epidemiology. 2023 Jun 1;158:70–83.
- 373 34. van der Linden N, Wildi K, Twerenbold R, Pickering JW, Than M, Cullen L, et al.
- 374 Combining High-Sensitivity Cardiac Troponin I and Cardiac Troponin T in the Early
- Diagnosis of Acute Myocardial Infarction. Circulation. 2018 Sep 4;138(10):989–99.
- 376 35. American College of Cardiology [Internet]. [cited 2024 Jan 21]. Utility of High-Sensitivity
- 377 Troponin T and I: Are They the Same? Available from: https://www.acc.org/Latest-in-
- 378 Cardiology/Articles/2019/11/21/07/26/http%3a%2f%2fwww.acc.org%2fLatest-in-
- 379 Cardiology%2fArticles%2f2019%2f11%2f21%2f07%2f26%2fUtility-of-High-Sensitivity-
- 380 Troponin-T-and-I
- 381 36. Willeit P, Welsh P, Evans JDW, Tschiderer L, Boachie C, Jukema JW, et al. High-
- 382 Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular
- 383 Outcomes in 154,052 Participants. J Am Coll Cardiol. 2017 Aug 1;70(5):558–68.
- 384 37. Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, et
 385 al. Development of the Instrument to assess the Credibility of Effect Modification

- Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ. 2020 Aug
 10;192(32):E901–6.
- 388 38. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on
- 389 choice of axis. J Clin Epidemiol. 2001 Oct;54(10):1046–55.
- 390 39. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al.
- 391 Recommendations for examining and interpreting funnel plot asymmetry in meta-
- analyses of randomised controlled trials. BMJ. 2011 Jul 22;343(jul22 1):d4002–d4002.
- 393 40. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a
- 394 simple, graphical test. BMJ. 1997 Sep 13;315(7109):629–34.
- 395 41. Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, et al. GRADE
- 396 Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors:
- 397 rating certainty in identification of groups of patients with different absolute risks. Journal
- of Clinical Epidemiology. 2020 May 1;121:62–70.
- 399 42. Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, et al. Use of GRADE for
- 400 assessment of evidence about prognosis: rating confidence in estimates of event rates
- 401 in broad categories of patients. BMJ. 2015 Mar 16;350:h870.